Picture of Harpoon Therapeutics logo

HARP — Harpoon Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMid CapMomentum Trap

Harpoon Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview

* Harpoon Therapeutics Inc  HARP.OQ   HARP.O  is expected
to show
a fall in quarterly revenue when it reports  results on August 8
(estimated). 
    * The South San Francisco California-based  company is
expected to
report  a 38.0% decrease in revenue to $5.148 million from $8.3
million a year ago, according to the mean estimate from 6
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Harpoon
Therapeutics Inc
is for a loss of 34 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Harpoon
Therapeutics Inc is $5.25​, above​ its last closing price
of $0.75. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.36       -0.38      -0.31     Beat    19.1
 Dec. 31 2023  -0.29       -0.47      -0.55     Missed  -17.8
 Sep. 30 2022  -0.57       -0.56      -0.35     Beat    37.8​
 Jun. 30 2022  -0.61       -0.56      -0.53     Beat    6.1
 ​​Mar.        -0.59       -0.55      -0.62     Missed  -13.7
 31 2022                                                
 Dec. 31 2021  -0.43       -0.42      -0.66     Missed  -55.7​
 Sep. 30 2021  -0.53       -0.52      -0.51     Beat    1.5
 Jun. 30 2021  -0.41       -0.43      -0.52     Missed  -19.7
 This summary was machine generated August 4 at 14:54 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on Harpoon Therapeutics

See all news